DJIA 17,798.49 -14.90 -0.08%
NASDAQ 5,127.53 11.38 0.22%
S&P 500 2,090.11 1.24 0.06%
market minute promo

Galena Biopharma, Inc. (NASDAQ: GALE)

1.49 -0.02 (-1.32%)

Quote as of

company name or ticker

Recent Quotes

GALE $1.49 -1.32%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.48
Previous Close $1.51
Daily Range $1.47 - $1.52
52-Week Range $1.10 - $2.39
Market Cap $241.2M
P/E Ratio -5.03
Dividend (Yield) $0.00 (0.0%)
Volume 706,496
Average Daily Volume 1,031,465
Current FY EPS -$0.28




Drug Makers

Galena Biopharma, Inc. (GALE) Description

Galena Biopharma Inc is a biotechnology company focused on discovering developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. Website:

News & Commentary Rss Feed

3 Things Galena Biopharma Inc. Wants You to Know

Galena Biopharma's headline numbers from its third-quarter results may not be telling the entire tale. Here are the three key points its management team wants you to know from its conference call.

Galena Biopharma (GALE) Stock Rating Upgraded at Oppenheimer

Galena Biopharma's 3rd-Quarter Report Is Nothing Short of Bizarre

Galena Biopharma's third-quarter loss widened from the prior-year period, but it's this odd announcement that has investors abuzz.

Here's Why Galena Biopharma's Stock Tanked Today

Galena Biopharma's stock crumbles after the company decides to divest its commercial product portfolio.

Galena Biopharma (GALE) Stock Declines on Earnings Miss

Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2015 Results - Earnings Call Transcript

Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society f

Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

4 Questions to Ask Ahead of Galena Biopharma's Third-Quarter Earnings Report

Set to report its Q3 results after the closing bell on Monday, Nov. 9, investors should be focused on these important points.

Is a Surprise Coming for Galena Biopharma (GALE) This Earnings Season?

Cancer Immunotherapy Developer Galena Biopharma Can't Win for Trying

Based on its share price, you'd think Galena's clinical pipeline hit a brick wall, but that just isn't the case.

See More GALE News...

GALE's Top Competitors

GALE $1.49 (-1.32%)
Current stock: GALE
AMGN $163.52 (-0.26%)
Current stock: AMGN
GILD $108.00 (0.20%)
Current stock: GILD
BIIB $293.21 (0.31%)
Current stock: BIIB